Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study
- PMID: 17235610
- DOI: 10.1007/s00213-006-0666-y
Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study
Abstract
Objectives: Previous studies have investigated the occupancy of the serotonin reuptake transporter (SERT) after clinical doses of citalopram and other selective serotonin reuptake inhibitors. In the present study, the occupancies of SERT after multiple doses of escitalopram and citalopram were compared using the radioligand [(123)I]ADAM and single photon emission computed tomography (SPECT).
Methods: Fifteen healthy subjects received escitalopram 10 mg/day (n = 6) or citalopram 20 mg/day (n = 9) for a total of 10 days. SERT occupancies in midbrain were determined with SPECT and [(123)I]ADAM at three different time points: at baseline (no medication) and at 6 and 54 h after last drug intake.
Results: At 6 h after the last dose, mean SERT occupancies were 81.5 +/- 5.4% (mean+/-SD) for escitalopram and 64.0 +/- 12.7% for citalopram (p < 0.01). At 54 h after the last dose, mean SERT occupancies were 63.3 +/- 12.1% for escitalopram and 49.0 +/- 11.7% for citalopram (p < 0.05). The plasma concentrations of the S-enantiomer were of the same magnitude in both substances. For both drugs, the elimination rate of the S-enantiomer in plasma was markedly higher than the occupancy decline rate in the midbrain.
Conclusion: The significantly higher occupancy of SERT after multiple doses of escitalopram compared to citalopram indicates an increased inhibition of SERT by escitalopram. The results can also be explained by an attenuating effect of R-citalopram on the occupancy of S-citalopram at the SERT.
Similar articles
-
In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.Psychopharmacology (Berl). 2006 Oct;188(3):263-72. doi: 10.1007/s00213-006-0486-0. Epub 2006 Sep 6. Psychopharmacology (Berl). 2006. PMID: 16955282 Clinical Trial.
-
Measuring SSRI occupancy of SERT using the novel tracer [123I]ADAM: a SPECT validation study.Eur J Nucl Med Mol Imaging. 2005 Nov;32(11):1329-36. doi: 10.1007/s00259-005-1912-y. Epub 2005 Aug 26. Eur J Nucl Med Mol Imaging. 2005. PMID: 16133377 Clinical Trial.
-
Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram.Int Clin Psychopharmacol. 2009 May;24(3):119-25. doi: 10.1097/YIC.0b013e32832a8ec8. Int Clin Psychopharmacol. 2009. PMID: 19367152 Review.
-
Imaging of serotonin transporters and its blockade by citalopram in patients with major depression using a novel SPECT ligand [123I]-ADAM.J Neural Transm (Vienna). 2006 May;113(5):659-70. doi: 10.1007/s00702-005-0429-7. Epub 2006 Feb 9. J Neural Transm (Vienna). 2006. PMID: 16465456 Clinical Trial.
-
[Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].Encephale. 2007 Dec;33(6):965-72. doi: 10.1016/j.encep.2007.11.001. Epub 2007 Dec 11. Encephale. 2007. PMID: 18789789 Review. French.
Cited by
-
Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.J Psychopharmacol. 2010 Aug;24(8):1143-52. doi: 10.1177/0269881109349835. Epub 2010 Feb 10. J Psychopharmacol. 2010. PMID: 20147575 Free PMC article. Review.
-
Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders.J Neurosci. 2010 Oct 27;30(43):14482-9. doi: 10.1523/JNEUROSCI.2409-10.2010. J Neurosci. 2010. PMID: 20980606 Free PMC article.
-
The interaction of escitalopram and R-citalopram at the human serotonin transporter investigated in the mouse.Psychopharmacology (Berl). 2014 Dec;231(23):4527-40. doi: 10.1007/s00213-014-3595-1. Epub 2014 May 9. Psychopharmacology (Berl). 2014. PMID: 24810106 Free PMC article.
-
Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability.Patient Prefer Adherence. 2012;6:853-61. doi: 10.2147/PPA.S22495. Epub 2012 Dec 4. Patient Prefer Adherence. 2012. PMID: 23271894 Free PMC article.
-
One-week escitalopram intake alters the excitation-inhibition balance in the healthy female brain.Hum Brain Mapp. 2022 Apr 15;43(6):1868-1881. doi: 10.1002/hbm.25760. Epub 2022 Jan 22. Hum Brain Mapp. 2022. PMID: 35064716 Free PMC article. Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources